美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Russell Investments Core Plus Bond ETF

24.22

-0.0228-0.09%

成交量：9

成交額：218

市值：5,679.12萬

市盈率：- -

高：24.22

開：24.24

低：24.22

收：24.24

52周最高：25.19

52周最低：24.22

股本：234.50萬

流通股本：234.50萬

量比：0.12

換手率：0.00%

股息：0.23

股息率：0.93%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

企業「出海」進階從產品輸出邁向能力輸出

480家藥企，最新營收、淨利潤來了

港股異動 | 樂普生物(02157)午後升逾5% 上半年收入按年增長12.1% 即將跑通CMG901的BD全鏈條

【券商聚焦】國投證券維持康諾亞-B（02162）買入評級指核心產品放量及BD兑現

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BD"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BD\",,,,,undefined,":{"symbol":"BD","market":"US","secType":"STK","nameCN":"Russell Investments Core Plus Bond ETF","latestPrice":24.218,"timestamp":1789502400000,"preClose":24.2408,"halted":0,"volume":9,"delay":0,"changeRate":-0.0009405630177221937,"floatShares":2345000,"shares":2345000,"eps":0,"marketStatus":"盤前交易","change":-0.0228,"latestTime":"09-16 04:10:35 EDT","open":24.2408,"high":24.218,"low":24.218,"amount":218,"amplitude":0,"askPrice":38.5,"askSize":100,"bidPrice":9.74,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789565400000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":24.218,"nav":24.324847,"aum":57041766.42,"dividendRate":0.00932,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.2408,"preClose":24.218,"latestTime":"16:04 EDT","volume":2,"amount":48.436,"timestamp":1789502648572,"change":0.0228,"changeRate":0.000941,"amplitude":0},"volumeRatio":0.11508941104528424},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BD\",,,,,undefined,":{"symbol":"BD","floatShares":2345000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.11508941104528424,"shares":2345000,"dividePrice":0.2257,"high":24.218,"amplitude":0,"preClose":24.2408,"low":24.218,"week52Low":24.218,"pbRate":"--","week52High":25.19,"institutionHeld":0,"latestPrice":24.218,"eps":0,"divideRate":0.00932,"volume":9,"delay":0,"ttmEps":0,"open":24.2408,"prevYearClose":25.08,"prevWeekClose":24.249,"prevMonthClose":24.7551,"prevQuarterClose":25.19,"fiveDayClose":24.615,"twentyDayClose":24.725},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BD\",params:#limit:5,,,undefined,":[{"date":"2026-09-02","symbol":"BD","amount":0.104028,"announcedDate":"2026-09-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-02","defaultRemindTime":1788355800000,"name":"Russell Investments Core Plus Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-04","payableDate":"2026-09-02","currency":"USD","dateTimestamp":1788321600000,"payDate":"2026-09-04"},{"date":"2026-08-04","symbol":"BD","amount":0.120736,"announcedDate":"2026-08-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-04","defaultRemindTime":1785850200000,"name":"Russell Investments Core Plus Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-06","payableDate":"2026-08-04","currency":"USD","dateTimestamp":1785816000000,"payDate":"2026-08-06"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BD\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-04","recordDate":"2026-08-04","paymentDate":"2026-08-06","value":0.120736,"currency":"USD"},{"executeDate":"2026-09-02","recordDate":"2026-09-02","paymentDate":"2026-09-04","value":0.104028,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BD\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667620418","title":"企業「出海」進階 從產品輸出邁向能力輸出","url":"https://stock-news.laohu8.com/highlight/detail?id=2667620418","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667620418?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 06:58","pubTimestamp":1789513080,"startTime":"0","endTime":"0","summary":"苏州纳微科技股份有限公司董事长江必旺在回答《证券日报》记者提问时说，中国药企的海外授权合作交易爆发，不仅涉及早期项目，更覆盖技术平台、临床开发及商业化全链条，这标志着中国药企从“产品输出”向“能力输出”的跃迁。除了“出海”之外，立足自身主营业务并推进产品多元化升级，蓄力夯实企业长期发展根基也是上市公司的共识。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-09-16/doc-inirykpk3177466.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-16/doc-inirykpk3177466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320971","title":"480家藥企，最新營收、淨利潤來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320971","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320971?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:39","pubTimestamp":1788867540,"startTime":"0","endTime":"0","summary":"2026年上半年，480家药企合计实现营收7,369.82亿元，同比增长+2.48%；实现归母净利润988.94亿元，同比增长+12.35%。荣昌生物营收58.53亿元，归母净利润46.62亿元，主要受海外授权合作首付款及里程碑款驱动，是板块利润暴增的最大来源。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircmeq9268445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773564","title":"港股異動 | 樂普生物(02157)午後升逾5% 上半年收入按年增長12.1% 即將跑通CMG901的BD全鏈條","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773564","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773564?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 13:54","pubTimestamp":1787810081,"startTime":"0","endTime":"0","summary":"消息面上，近日，乐普生物发布截至2026年6月30日止六个月业绩，收入5.22亿元，同比增长12.1%；公司拥有人应占利润2739.3万元，同比下降34.4%；每股基本盈利0.02元。国联民生证券发布研报称，乐普生物CMG901全球权益授权阿斯利康、MRG007大中华区外权益授权ArriVent，实现研发能力变现。在商业模式上，公司已成功构建并验证了国内商业化能力，同时即将跑通CMG901的BD全链条。这标志乐普生物能够通过国内商业化和海外授权双轮驱动，持续优化收入结构。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","02157","VXUS","BK1161","KCAI","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662623760","title":"【券商聚焦】國投證券維持康諾亞-B（02162）買入評級 指核心產品放量及BD兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2662623760","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662623760?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 14:06","pubTimestamp":1787724376,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券发布研报指，康诺亚-B 2026年中期实现营业收入6.17亿元人民币，同比增长24%；实现净利润12.18亿元人民币，上年同期为亏损0.79亿元。收入及利润变化主要受核心产品康悦达销售放量及海外BD里程碑收入确认影响。截至2026年6月30日，公司现金及金融资产合计32.42亿元人民币，较年初增长65%。考虑到康悦达医保放量、海外BD授权持续兑现及CM512等管线临床进展，维持“买入-A”评级，根据DCF模型给予6个月目标价90.37港元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989484","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","KCE","BD","02162"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":10,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BD\",params:#limit:6,delay:false,,,undefined,":[]}}